Age-related macular degeneration (AMD) is one the most common causes of severe vision loss in people over 50 years old.

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing ...

The California Institute for Regenerative Medicine (CIRM), the state's stem cell agency, has awarded a two-year, $6 million ...

The FDA announced marketing authorization of a form of light therapy as the first-ever treatment for dry age-related macular ...

The Valeda ® Light Delivery System (LumiThera, Inc.) is the first ever FDA-authorized treatment for vision loss in dry AMD, the manufacturer reported. The technology was evaluated in the LIGHTSITE III ...

4). AMD progressively damages the center of the retina, the light-detecting region at the back of the eye. Recent data ...

Dry AMD is one of the two forms of the ocular disease that ranks as the leading cause of blindness in adults over age 65, driven by the slow loss of photoreceptor cells over time. Dry AMD begins ...

Neovascular AMD is an advanced form of the condition, also known as “exudative AMD" or “wet macular degeneration.” The wet form is less common than the dry form of AMD, occurring in roughly 10–15% of ...

Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...